Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STP938 |
Synonyms | |
Therapy Description |
STP938 inhibits CTPS1, which potentially induces tumor cell death (Blood (2022), 140 (Supplement 1): 6014-6015). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STP938 | STP-938|STP 938 | STP938 inhibits CTPS1, which potentially induces tumor cell death (Blood (2022), 140 (Supplement 1): 6014-6015). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05463263 | Phase Ib/II | STP938 | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Recruiting | USA | GBR | FRA | 0 |
NCT06297525 | Phase I | STP938 | Study of STP938 in Advanced Solid Tumours | Recruiting | USA | 0 |